GlassScriptPhysician profile
Kenneth John Moquin
NPI 1124181755
$145,617.27
in general payments reported to CMS, 2019-2025
25 companies · $13K in 2025
The $13K reported for 2025 was more than what 95% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $14K · 2021: $10K · 2022: $26K · 2023: $12K · 2024: $9,953 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $7,225 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,710 · Food and Beverage: $4,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,750.00 |
| Travel and Lodging | $7,224.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,710.00 |
| Food and Beverage | $4,620.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $127,753.59 | 2019-2025 | Renasys Touch, Pico, Pico 7 |
| Abbvie INC. | $5,322.41 | 2023-2025 | |
| Cardinal Health 200 LLC | $4,027.43 | 2019 | |
| Allergan, INC. | $3,924.16 | 2019-2021 | |
| Integra Lifesciences Corporation | $1,059.77 | 2020-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Mentor Worldwide LLC | $444.67 | 2019-2022 | |
| Kerecis Limited | $320.90 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Tela Bio, INC. | $304.61 | 2019-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Axogen | $298.07 | 2023-2024 | Avance Nerve Graft, Axoguard Nerve Cap, Axoguard Ha+ Nerve Protector |
| Avita Medical Americas, LLC | $280.49 | 2024-2025 | Cohealyx, Recell, Permeaderm |
| Checkpoint Surgical, INC | $235.86 | 2021 | |
| Stryker Corporation | $199.43 | 2020-2023 | Hydroset, Na |
| Sientra, INC. | $155.51 | 2021 | |
| Organogenesis INC. | $142.86 | 2024 | Puraply Franchise |
| Polynovo North America LLC | $141.17 | 2024 | Novosorb Btm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $125.59 | 2021 | |
| Depuy Synthes Sales INC. | $123.75 | 2023 | Trumatch |
| Innovation Technologies INC | $122.77 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $114.63 | 2022 | |
| Acell, INC. | $112.74 | 2019 | |
| Kls-Martin L.P. | $109.83 | 2019 | |
| Mimedx Group, INC. | $84.20 | 2025 | |
| Endo Pharmaceuticals INC. | $79.39 | 2019-2023 | Xiaflex |
| Tei Biosciences INC | $78.45 | 2019 | |
| Ethicon US, LLC | $54.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Moquin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.